Highlights
Profile claimed by owner
About
Antimicrobial Agents for Treating Drug-resistant Mycobacteria
Molbrick is a start-up developing novel antimicrobial agents to treat drug-resistant mycobacteria. It has designed small-molecule target cellular compartments that are essential for DNA replication. Molbrick's platform technology was developed in Dr. Barak Akabayov's lab at Ben-Gurion University.
Identity
| Name | Molbrick |
|---|---|
| Slug | molbrick |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4KLX5ogKDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | South District |
| HQ city | Be'er Sheva |
| HQ address | Beer-Sheva, Israel |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMicroorganisms
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
pharmaceuticalsmicrobiology
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}